Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 1678584, 10 pages
https://doi.org/10.1155/2017/1678584
Research Article

Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer

1Department of Surgery, Medical University of Vienna and Gastroesophageal Tumor Unit, Comprehensive Cancer Center (CCC), Spitalgasse 23, 1090 Vienna, Austria
2Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria

Correspondence should be addressed to S. F. Schoppmann; ta.ca.neiwinudem@nnamppohcs.naitsabes

Received 5 December 2016; Accepted 3 May 2017; Published 27 June 2017

Academic Editor: Amosy M'Koma

Copyright © 2017 G. Jomrich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. J. V. Reynolds, C. Muldoon, D. Hollywood et al., “Long- term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer,” Annals of Surgery, vol. 245, no. 5, pp. 707–716, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. B. H. Burmeister, B. M. Smithers, V. Gebski et al., “Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial,” The Lancet Oncology, vol. 6, no. 9, pp. 659–668, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Yuequan, C. Shifeng, and Z. Bing, “Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery,” The Annals of Thoracic Surgery, vol. 90, no. 3, pp. 908–913, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Bollschweiler, S. E. Baldus, W. Schroder, P. M. Schneider, and A. H. Holscher, “Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?” Journal of Surgical Oncology, vol. 94, no. 5, pp. 355–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. D. Christein, E. F. Hollinger, and K. W. Millikan, “Prognostic factors associated with resectable carcinoma of the esophagus,” The American Surgeon, vol. 68, no. 3, pp. 258–263, 2002. View at Google Scholar
  7. M. A. Eloubeidi, R. Desmond, M. R. Arguedas, C. E. Reed, and C. M. Wilcox, “Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status,” Cancer, vol. 95, no. 7, pp. 1434–1443, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Gertler, H. J. Stein, R. Langer et al., “Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system,” Annals of Surgery, vol. 253, no. 4, pp. 689–698, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. E. A. Griffiths, Z. Brummell, G. Gorthi, S. A. Pritchard, and I. M. Welch, “Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses,” Journal of Surgical Oncology, vol. 93, no. 4, pp. 258–267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. O. A. Khan, C. Alexiou, I. Soomro, J. P. Duffy, W. E. Morgan, and F. D. Beggs, “Pathological determinants of survival in node-negative oesophageal cancer,” The British Journal of Surgery, vol. 91, no. 12, pp. 1586–1591, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. Omloo, S. M. Lagarde, J. B. Hulscher et al., “Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial,” Annals of Surgery, vol. 246, no. 6, pp. 992–1000, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. W. Rice, V. W. Rusch, H. Ishwaran, E. H. Blackstone, and Worldwide Esophageal Cancer C, “Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals,” Cancer, vol. 116, no. 16, pp. 3763–3773, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Nagaoka, T. Yoshida, J. Akiyoshi et al., “Serum C-reactive protein levels predict survival in hepatocellular carcinoma,” Liver International, vol. 27, no. 8, pp. 1091–1097, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Szkandera, M. Stotz, G. Absenger et al., “Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients,” British Journal of Cancer, vol. 110, no. 1, pp. 183–188, 2014. View at Google Scholar
  17. J. Szkandera, A. Gerger, B. Liegl-Atzwanger et al., “Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients,” British Journal of Cancer, vol. 109, no. 9, pp. 2316–2322, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Zhou, X. Cai, Q. Liu, Z. Y. Jian, H. Li, and K. J. Wang, “Prognostic role of C-reactive protein in urological cancers: a meta-analysis,” Scientific Reports, vol. 5, p. 12733, 2015. View at Google Scholar
  19. D. A. Deans, B. H. Tan, S. J. Wigmore et al., “The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer,” British Journal of Cancer, vol. 100, no. 1, pp. 63–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L. M. Forrest, D. C. McMillan, C. S. McArdle, W. J. Angerson, and D. J. Dunlop, “Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer,” British Journal of Cancer, vol. 89, no. 6, pp. 1028–1030, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. A. B. Crumley, D. C. McMillan, M. McKernan, A. C. McDonald, and R. C. Stuart, “Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer,” British Journal of Cancer, vol. 94, no. 5, pp. 637–641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Melling, A. Gruning, M. Tachezy et al., “Glasgow prognostic score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment,” Surgery, vol. 159, no. 6, pp. 1548–1556, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Dutta, A. B. Crumley, G. M. Fullarton, P. G. Horgan, and D. C. McMillan, “Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer,” World Journal of Surgery, vol. 35, no. 8, pp. 1861–1866, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. D. J. Pinato, R. J. Shiner, M. J. Seckl, J. Stebbing, R. Sharma, and F. A. Mauri, “Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer,” British Journal of Cancer, vol. 110, no. 8, pp. 1930–1935, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Kinoshita, H. Onoda, N. Imai et al., “The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma,” Annals of Surgical Oncology, vol. 22, no. 3, pp. 803–810, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Lindenmann, N. Fink-Neuboeck, M. Koesslbacher et al., “The influence of elevated levels of C-reactive protein and hypoalbuminemia on survival in patients with advanced inoperable esophageal cancer undergoing palliative treatment,” Journal of Surgical Oncology, vol. 110, no. 6, pp. 645–650, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Lindenmann, N. Fink-Neuboeck, A. Avian et al., “Preoperative Glasgow prognostic score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy,” European Journal of Surgical Oncology, vol. 43, no. 2, pp. 445–453, 2017. View at Google Scholar
  28. Q. Ma, W. Liu, R. Jia et al., “Inflammation-based prognostic system predicts postoperative survival of esophageal carcinoma patients with normal preoperative serum carcinoembryonic antigen and squamous cell carcinoma antigen levels,” World Journal of Surgical Oncology, vol. 14, p. 141, 2016. View at Google Scholar
  29. R. Tian, F. Zhang, P. Sun et al., “The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma,” Oncotarget, vol. 7, no. 41, pp. 67485–67494, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. S. B. Edge and C. C. Compton, “The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM,” Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471–1474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Haslacher, T. Szekeres, M. Gerner et al., “The effect of storage temperature fluctuations on the stability of biochemical analytes in blood serum,” Clinical Chemistry and Laboratory Medicine, 2016. View at Publisher · View at Google Scholar
  32. D. J. Brown, R. Milroy, T. Preston, and D. C. McMillan, “The relationship between an inflammation-based prognostic score (Glasgow prognostic score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer,” Journal of Clinical Pathology, vol. 60, no. 6, pp. 705–708, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ishizuka, H. Nagata, K. Takagi, T. Horie, and K. Kubota, “Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer,” Annals of Surgery, vol. 246, no. 6, pp. 1047–1051, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. D. C. McMillan, “Systemic inflammation, nutritional status and survival in patients with cancer,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 3, pp. 223–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. D. C. McMillan, “An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer,” The Proceedings of the Nutrition Society, vol. 67, no. 3, pp. 257–262, 2008. View at Google Scholar
  36. M. J. Proctor, D. S. Morrison, D. Talwar et al., “An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow inflammation outcome study,” British Journal of Cancer, vol. 104, no. 4, pp. 726–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. X. L. Xu, H. Q. Yu, W. Hu, Q. Song, and W. M. Mao, “A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma,” PloS One, vol. 10, no. 9, article e0138657, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Schemper and T. L. Smith, “A note on quantifying follow-up in studies of failure time,” Controlled Clinical Trials, vol. 17, no. 4, pp. 343–346, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Gleiss, R. Zeillinger, E. I. Braicu, F. Trillsch, I. Vergote, and M. Schemper, “Statistical controversies in clinical research: the importance of importance,” Annals of Oncology, vol. 27, no. 7, pp. 1185–1189, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. H. F. Dvorak, “Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing,” The New England Journal of Medicine, vol. 315, no. 26, pp. 1650–1659, 1986. View at Publisher · View at Google Scholar
  43. W. S. Tillett and T. Francis, “Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus,” The Journal of Experimental Medicine, vol. 52, no. 4, pp. 561–571, 1930. View at Publisher · View at Google Scholar
  44. S. Shrotriya, D. Walsh, N. Bennani-Baiti, S. Thomas, and C. Lorton, “C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review,” PloS One, vol. 10, no. 12, article e0143080, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Huang, J. F. Feng, J. S. Liu, and Q. X. Chen, “Prognostic role of serum C-reactive protein in esophageal cancer: a systematic review and meta-analysis,” Therapeutics and Clinical Risk Management, vol. 11, pp. 89–94, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Delmore, “Assessment of nutritional status in cancer patients: widely neglected?” Supportive Care in Cancer, vol. 5, no. 5, pp. 376–380, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Anandavadivelan and P. Lagergren, “Cachexia in patients with oesophageal cancer,” Nature Reviews. Clinical Oncology, vol. 13, no. 3, pp. 185–198, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. A. B. Crumley, R. C. Stuart, M. McKernan, and D. C. McMillan, “Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer?” World Journal of Surgery, vol. 34, no. 10, pp. 2393–2398, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Al-Shaiba, D. C. McMillan, W. J. Angerson, E. Leen, C. S. McArdle, and P. Horgan, “The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases,” British Journal of Cancer, vol. 91, no. 2, pp. 205–207, 2004. View at Publisher · View at Google Scholar
  50. N. Wu, G. Chen, H. Hu, L. Pang, and Z. Chen, “Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas,” Nutrition and Cancer, vol. 67, no. 3, pp. 481–485, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. E. F. Leitch, M. Chakrabarti, J. E. Crozier et al., “Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer,” British Journal of Cancer, vol. 97, no. 9, pp. 1266–1270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Yotsukura, T. Ohtsuka, K. Kaseda, I. Kamiyama, Y. Hayashi, and H. Asamura, “Value of the Glasgow prognostic score as a prognostic factor in resectable non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 11, no. 8, pp. 1311–1318, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Polterauer, C. Grimm, V. Seebacher et al., “The inflammation-based Glasgow prognostic score predicts survival in patients with cervical cancer,” International Journal of Gynecological Cancer, vol. 20, no. 6, pp. 1052–1057, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. D. C. McMillan, J. E. Crozier, K. Canna, W. J. Angerson, and C. S. McArdle, “Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer,” International Journal of Colorectal Disease, vol. 22, no. 8, pp. 881–886, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. D. C. McMillan, “The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer,” Cancer Treatment Reviews, vol. 39, no. 5, pp. 534–540, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. M. J. Proctor, D. S. Morrison, D. Talwar et al., “A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study,” European Journal of Cancer, vol. 47, no. 17, pp. 2633–2641, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Furukawa, H. Shiba, K. Haruki et al., “The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases,” Oncology Letters, vol. 4, no. 2, pp. 324–328, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. O. T. Ranzani, F. G. Zampieri, D. N. Forte, L. C. Azevedo, and M. Park, “C-reactive protein/albumin ratio predicts 90-day mortality of septic patients,” PloS One, vol. 8, no. 3, article e59321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. P. van Hagen, M. C. Hulshof, J. J. van Lanschot et al., “Preoperative chemoradiotherapy for esophageal or junctional cancer,” The New England Journal of Medicine, vol. 366, no. 22, pp. 2074–2084, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Shapiro, D. van Klaveren, S. M. Lagarde et al., “Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery,” The British Journal of Surgery, vol. 103, no. 8, pp. 1039–1047, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Otowa, T. Nakamura, G. Takiguchi et al., “Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer,” Diseases of the Esophagus, vol. 29, no. 2, pp. 146–151, 2016. View at Publisher · View at Google Scholar · View at Scopus